Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?

As of 4 August 2025, the valuation grade for Aurinia Pharmaceuticals, Inc. has moved from attractive to fair. The company appears to be fairly valued based on its current P/E ratio of 19, which is slightly below the peer average of approximately 20.87, and an EV to EBITDA ratio of 11.23, which is also competitive within the industry. Additionally, the PEG ratio of 0.10 suggests that the stock may be undervalued relative to its growth potential.
In comparison to its peers, Aurinia's valuation metrics are relatively strong, particularly when contrasted with companies like Rhythm Pharmaceuticals, Inc., which has a negative P/E ratio, indicating significant challenges. The company's return performance has been noteworthy, with a year-to-date return of 43.54% compared to the S&P 500's 12.22%, reinforcing the notion that Aurinia is performing well in the market despite its fair valuation status.